ArticleEuropean journal of medical research2025
Identifying chemotherapy beneficiaries in nasal and paranasal sinus cancers: epidemiological trends and machine learning insights.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of 5-year survival rates and prognostic factors between adenoid cystic carcinoma and squamous cell carcinoma of the maxillary sinus: a SEER database analysis.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies on the epidemiological characteristics, treatment strategies and prognosis of nasal and paranasal sinus cancer are still relatively limited.
methodsThis study analyzed the age-adjusted incidence rates of nasal and paranasal sinus cancer from 1975 to 2020 using SEER database data. We conducted an in-depth examination of patients diagnosed between 2004 and 2015 with SEER*Stat software. A retrospective study from Fujian Provincial Cancer Hospital (2013-2020) provided an external validation set. Multiple imputation methods in R were used to address missing data. Survival analyses were performed using Kaplan-Meier and Cox proportional hazards models. Additionally, ten advanced machine learning models were utilized and evaluated in Python to predict patient survival outcomes.
resultsThis study analyzed data from 3,190 patients. The annual percent change (APC) in incidence rates per 100 000 person-years was 0.36 until 2012, subsequently decreasing to - 1.79. Among various predictive models, the gradient boosting classifier demonstrated superior performance with an area under the curve (AUC) of 0.699 and an accuracy rate of 0.708. Chemotherapy did not significantly influence overall mortality risk (HR = 0.93, 95% CI 0.82-1.05, P = 0.27). Chemotherapy showed potential benefits in specific patient subgroups.
conclusionsThis study revealed a declining trend in incidence rates beginning in 2012. The gradient boosting model demonstrated robust performance, playing a crucial role in predicting patient prognosis and the significance of chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.